Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830606 | 0.93 | POLB (0.49) | KDM4EALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL3274096 | 0.85 | HRH3 (0.55) | ALDH1A1SMN1; SMN2NPC1POLBRAB9A | |
| SCHEMBL6181435 | 0.83 | ALDH1A1 (0.49) | KDM4EALDH1A1SMN1; SMN2POLBHRH3 | |
| SCHEMBL3540865 | 0.82 | PARP1 (0.43) | ALDH1A1SMN1; SMN2POLBLMNASIRT6 | |
| Hydrochloric Acid SCHEMBL16694716 | 0.81 | HTT (0.50) | KDM4EALDH1A1SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL8973048 | 0.80 | MAPT (0.50) | ALDH1A1SMN1; SMN2POLBLMNASIGMAR1 | |
| SCHEMBL23246848 | 0.80 | POLB (0.48) | KDM4EALDH1A1SMN1; SMN2POLBTDP1 | |
| SCHEMBL23246845 | 0.80 | POLB (0.48) | KDM4EALDH1A1SMN1; SMN2POLBTDP1 | |
| SCHEMBL9235807 | 0.80 | HRH3 (0.61) | KDM4EALDH1A1SMN1; SMN2HRH3SIGMAR1 | |
| SCHEMBL13419606 | 0.80 | CYP19A1 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | KDM4E 862/4885ALDH1A1 1046/4885SMN1; SMN2 1521/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | KDM4E 712/4885ALDH1A1 1393/4885SMN1; SMN2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.